Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.55 |
| ▸ | AR | P10275 | 4/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.48 |
| ▸ | BTK | Q06187 | 3/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 2/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30720917 | 1.00 | CRBN (0.55) | CRBNARDDB1BTKCDK9 | |
| SCHEMBL29132109 | 0.94 | CRBN (0.57) | CRBNARDDB1BTKCDK9 | |
| SCHEMBL29928196 | 0.94 | CRBN (0.57) | CRBNARDDB1BTKCDK9 | |
| SCHEMBL20231763 | 0.92 | CRBN (0.59) | CRBNARDDB1BTKCDK9 | |
| SCHEMBL29927733 | 0.92 | CRBN (0.59) | CRBNARDDB1BTKCDK9 | |
| SCHEMBL29132140 | 0.92 | CRBN (0.59) | CRBNARDDB1BTKCDK9 | |
| SCHEMBL29132225 | 0.92 | CRBN (0.57) | CRBNARDDB1BTKCDK9 | |
| SCHEMBL29927925 | 0.92 | CRBN (0.57) | CRBNARDDB1BTKCDK9 | |
| SCHEMBL31619110 | 0.91 | CRBN (0.58) | CRBNARDDB1BTKCDK9 | |
| SCHEMBL20234891 | 0.91 | CRBN (0.58) | CRBNARDDB1BTKCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-11981683-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4308557-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022198112-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | CRBN 2/4885AR 3324/4885DDB1 947/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | CRBN 2/4885AR 2492/4885DDB1 3539/4885 |
| US-11981683-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, MDM2 | CRBN 2/4885AR 3324/4885DDB1 947/4885 |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | CRBN 2/4885AR 3324/4885DDB1 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.